Endovia Health Sciences, Inc. (EDVA) stock forecast & analysis
0.2051
NYSE American · USD
Down: -0.0255, -11.1%
1 analysis
- Open
- 0.2511
- Previous close
- 0.2306
- Day range
- 0.1693 – 0.3090
- 52-week range
- 0.1690 – 13.40
- Volume (shares)
- 65.77M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 6.92M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- -1.09
- Market cap
- 1.42M
Market Scanner’s AI analysis of Endovia Health Sciences, Inc. (EDVA), updated September 2026: Endovia Health Sciences (EDVA) news highlights FDA milestone and funding for CannEpil® amid technical downtrend
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Endovia Health Sciences, Inc. (EDVA) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Endovia Health Sciences (EDVA) news highlights FDA milestone and funding for CannEpil® amid technical downtrend
Recent analyses for Endovia Health Sciences (EDVA) covered a significant FDA regulatory milestone and initial funding for its CannEpil® veterinary development program, alongside a favorable shift in federal policy for botanical drugs. Concurrently, technical indicators showed the stock trading below key moving averages with strong selling pressure and a notable downtrend over the past 7, 30, and 91 days.
EDVA news & sentiment
News sentiment was positive, highlighting a significant FDA regulatory milestone and initial funding for Endovia Health Sciences' veterinary program, supported by favorable policy shifts. Social media discussion was not covered in the provided notes.
EDVA technical picture
EDVA's stock traded below its 50-day and 200-day simple moving averages, showing a strong downtrend with negative 7-day, 30-day, and 91-day changes. Momentum indicators like RSI and MFI suggested oversold conditions and significant selling pressure, while the MACD confirmed bearish momentum.
Fundamentals
Endovia Health Sciences (EDVA) reported negative trailing twelve-month revenue and gross profit, alongside a significantly negative operating margin. The company's most recent annual period showed substantial net losses and negative operating income, with a current market capitalization of $1.42M and a stock price below $1.00.
Factors discussed — upside
- Initial funding round achieved
- Key FDA regulatory milestone for CannEpil® veterinary development program
- Growing federal support for botanical drug pathways
- Historic shift in federal cannabinoid policy
Factors discussed — risks
- Stock trading below 50-day and 200-day simple moving averages
- Significant downtrend indicated by 7-day, 30-day, and 91-day price changes
- Extremely low Money Flow Index (MFI) indicating significant selling pressure
- MACD below its signal line confirming bearish momentum
- Negative trailing twelve-month (TTM) operating margin and gross profit
- Regulatory developments
- Funding environment
- Technical indicators
- Financial health
Summary updated .
EDVA technical indicators
Common technical indicators for EDVA, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.34 | Price below |
| 10-day exponential moving average | 0.24 | Price below |
| Relative strength index (14-day) | 31.72 | Neutral |
| MACD line (12/26/9) | -0.0420 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.19 – 0.34 | Price inside the bands |
Analyses
Recent EDVA.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Endovia Health Sciences, Inc.?
- The bull case for Endovia Health Sciences (EDVA) centers on recent achievements including an initial funding round and a key FDA regulatory milestone for its CannEpil® veterinary development program. This progress is supported by a favorable policy environment, characterized by growing federal support for botanical drug pathways and a shift in federal cannabinoid policy.
- What are the risks for Endovia Health Sciences, Inc.?
- Risks for Endovia Health Sciences (EDVA) include the stock trading significantly below its 50-day and 200-day moving averages, reflecting a strong downtrend indicated by recent short-term and long-term price changes. Technical indicators such as an extremely low Money Flow Index and a bearish MACD signal substantial selling pressure and negative momentum, compounded by a highly negative TTM operating margin and gross profit.
- Is Endovia Health Sciences, Inc. bullish or bearish?
- Recent AI analyses of Endovia Health Sciences, Inc. examined factors on both sides. Discussed upside: The bull case for Endovia Health Sciences (EDVA) centers on recent achievements including an initial funding round and a key FDA regulatory milestone for its CannEpil® veterinary development program. This progress is supported by a favorable policy environment, characterized by growing federal support for botanical drug pathways and a shift in federal cannabinoid policy. Discussed risks: Risks for Endovia Health Sciences (EDVA) include the stock trading significantly below its 50-day and 200-day moving averages, reflecting a strong downtrend indicated by recent short-term and long-term price changes. Technical indicators such as an extremely low Money Flow Index and a bearish MACD signal substantial selling pressure and negative momentum, compounded by a highly negative TTM operating margin and gross profit. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Endovia Health Sciences, Inc.?
- News sentiment was positive, highlighting a significant FDA regulatory milestone and initial funding for Endovia Health Sciences' veterinary program, supported by favorable policy shifts. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Endovia Health Sciences, Inc.?
- Every analysis of Endovia Health Sciences, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh EDVA.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.